Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenishaw Regulatory News (RSW)

Share Price Information for Renishaw (RSW)

Share Price is delayed by 15 minutes
Get Live Data
5,180.00    -50.00 (-0.96%)
Bid:
5,175.00
Ask:
5,180.00
Spread: 5.00 (0.097%)
Market Cap: £3.77b
RSW Live PriceLast checked at - London Stock Exchange

Intraday Renishaw Share Chart

Annual Financial Report

23 Aug 2010 07:00

RNS Number : 3895R
Renishaw PLC
23 August 2010
 



Renishaw plc (the "Company")

 

Annual Report and Accounts 2010 and new Articles of association

 

Further to the publication of the Company's preliminary announcement of its annual results for the year ended 30 June 2010 on 28 July 2010 (the "Preliminary Announcement"), it is confirmed that two copies of the following have been submitted to the UK Listing Authority:

1. Annual Report and Accounts for the year ended 30 June 2010 containing Notice of AGM;

2. Proxy Form; and

3. Proposed new articles of association.

These will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, whose address is set out below.

UK Listing Authority

Financial Services Authority

25 The North Colonnade

Canary Wharf

London

E14 5HS

Tel. No. (0)20 676 1000

 

The Annual Report and Accounts 2010 will also be available on www.renishaw.com

In compliance with the Disclosure and Transparency Rules, the following information, together with the Preliminary Announcement (available on www.renishaw.com), forms the information required to be communicated to the media in unedited full text as required by DTR 6.3.5:

 

Risk Management

 

Worldwide economic situation

In response to the global economic downturn, the Group initiated a significant cost reduction programme at the start of the 2009 calendar year, with a targeted £10m reduction in annual overhead expenditure, a redundancy programme involving 437 personnel and the remaining staff accepting a voluntary 20% reduction in pay from February 2009.

Order intake has shown a significant improvement since the end of the Group's last financial year, with orders received exceeding sales for the current financial year. As profits returned during the first half of the current financial year, full pay was reinstated in stages, effectively for the full year.

The Board continues to maintain a tight control on costs and additional headcount is approved where vital to support the increasing order book.

Whilst the signs of an improving global economy are encouraging, the upturn may be slower than anticipated, highlighting that Group growth targets may be at risk.

Order book

Orders from customers generally involve short lead times with the outstanding order book at any time being around one month's worth of sales value.

This limited forward order visibility restricts the Group's ability to forecast demand accurately and therefore requires maximum production flexibility and appropriate inventory levels.

Research and development

The Group invests heavily in research and development in order to develop new products and processes to maintain the long-term growth of the Group. This research and development encompasses new innovative products within our core metrology business, as well as the application of our technology in the area of healthcare, including dental and specific applications in the medical field.

The development of new products and processes involves risk, such as with development time, which may take longer than originally forecast and hence involve more cost. Also, being at the leading edge of new technology, there are uncertainties whether new developments will perform as planned and in some cases, projects may need to be halted.

Research and development also involves beta testing at our major customers to ensure that new products will meet the needs of the market at the right price.

Expenditure is only capitalised once the commercial and technical feasibility of a product is proven.

These risks are minimised by operating strictly managed research and development programmes with regular reviews against milestones achieved and against forecast business plans.

Defined benefit pension schemes

With the closure of the UK and Irish defined benefit schemes to new employees and future accruals for existing members, the major risk surrounding accounting for pension costs and future funding arise from investment performance within the portfolio and actuarial assumptions.

This year has seen the Consolidated statement of comprehensive income and expense bear an actuarial loss of £14.9m (2009 loss of £13.0m).

The UK defined benefit scheme is secured by a registered charge on certain of the Group's UK properties. The Pension Regulator has confirmed that it does not propose to issue any scheme funding directions under Part 3 of the Pensions Act 2004.

Treasury

With the concentration of manufacturing in the UK, Ireland and India, there is an exposure to fluctuating currencies on export sales, largely in respect of the US Dollar, Euro and Japanese Yen. The Group managed the risk in respect of the year just ended by using forward contracts to hedge forecast income streams for its Euro and Japanese Yen exposures and for a proportion of its US Dollar income streams.

The hedging contracts outstanding at the end of the year were marked to market at the year end and the Consolidated statement of comprehensive income and expense shows a profit for the year of £5.6m (after tax) on these outstanding contracts, with the cash flow hedging reserve changing from a loss of £5.4m at the end of June 2009 to a profit of £0.2m at the end of June 2010.

The Group continues to be hedged against current levels of Euro and Japanese Yen receivables on a rolling three-and-a-half year basis, and against a proportion of forecast US Dollar receivables on a rolling fourteen-month basis. The Group monitors the effectiveness of its hedging policies regularly and any ineffective proportions may need to be accounted for in the Consolidated income statement. The policy relating to the Group's hedging practices is noted within the treasury policies on page 14.

Tax

Significant judgement is required in determining the effective tax rate and in evaluating certain tax positions. Tax provisions are adjusted as a result of changing facts and circumstances, such as case law, progress of tax audits or when an event occurs requiring a change in tax provisions. Management regularly assesses the appropriateness of tax provisions.

 

Directors Responsibility Statement

 

We confirm that to the best of our knowledge:

(a) the financial statements, prepared in accordance with the accounting standards referred to in the Statement of directors' responsibilities, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole; and

(b) the Financial review includes a fair review of the development and performance of the business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face.

 

 

 

20 August 2010

 

Renishaw plc

Registered office: New Mills, Wotton-under-Edge, Gloucestershire GL12 8JR UK

Registered number: 1106260

Contact name: Norma Tang

Contact telephone: 01453 52445

www.renishaw.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSVBLBLBVFXBBK
Date   Source Headline
6th May 20267:00 amRNSTrading Statement
20th Apr 20267:00 amRNSTrading Statement
8th Apr 20267:00 amRNSBoard Changes
11th Feb 20267:00 amRNSHalf-year Financial Report
29th Jan 202612:00 pmRNSNotice of Half-year Results
28th Nov 202511:00 amRNSHolding(s) in Company
28th Nov 202511:00 amRNSHolding(s) in Company
27th Nov 20256:29 pmRNSHolding(s) in Company
27th Nov 20255:00 pmRNSDirector/PDMR Shareholding
26th Nov 20251:32 pmRNSResult of AGM
26th Nov 20258:30 amRNSShareholdings update
29th Oct 20254:00 pmRNSDirector/PDMR Shareholding
23rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
23rd Oct 20257:00 amRNSTrading Statement
21st Oct 20253:02 pmRNSVoting Arrangement
21st Oct 20253:00 pmRNSHolding(s) in Company
21st Oct 20253:00 pmRNSHolding(s) in Company
3rd Oct 20257:00 amRNSAnnual Financial Report
24th Sep 20257:00 amRNSDirector/PDMR Shareholding
23rd Sep 20257:00 amRNSNew reporting segments for FY2026
18th Sep 20257:00 amRNSFinal Results
21st Aug 20257:00 amRNSBoard Change and Trading Update
13th Aug 20257:00 amRNSDirectorate Change
17th Jun 20257:00 amRNSCapital Markets Day
8th May 20257:00 amRNSTrading Statement
14th Apr 20259:49 amRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSHalf-year Report
9th Dec 20242:02 pmRNSDeath of Sir David McMurtry
27th Nov 20242:44 pmRNSResult of AGM
29th Oct 20241:28 pmRNSDirector/PDMR Shareholding
24th Oct 20247:00 amRNSTrading Statement
27th Sep 20247:15 amRNSAnnual Financial Report
12th Sep 20247:00 amRNSFinal Results
29th Aug 20242:00 pmRNSNotice of Results
1st Jul 20247:00 amRNSDirectorate Change
13th Jun 20247:00 amRNSDirectorate Change
16th May 20242:25 pmRNSAGM Voting Results Update Statement
8th May 20247:00 amRNSTrading Statement
2nd Apr 20245:19 pmRNSStatement regarding Renishaw plc
6th Feb 20247:00 amRNSHalf-year Report
30th Jan 202410:30 amRNSChange of Adviser
23rd Jan 20249:00 amRNSNotice of Half-year Results
29th Nov 20232:47 pmRNSResult of AGM
26th Oct 20237:00 amRNSTrading Statement
13th Oct 20237:00 amRNSNotice of AGM
3rd Oct 20237:00 amRNSAnnual Financial Report
19th Sep 20237:00 amRNSFinal Results
13th Sep 20237:00 amRNSRevised date for publication of results
21st Aug 20233:00 pmRNSDirectorate Change
12th Jul 20232:30 pmRNSVoting Arrangement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.